2022 update of the drug resistance mutations in HIV-1

Annemarie M Wensing; Vincent Calvez; Francesca Ceccherini-Silberstein; Charlotte Charpentier; Huldrych F Günthard; Roger Paredes; Robert W Shafer; Douglas D Richman

2022 update of the drug resistance mutations in HIV-1

Top Antivir Med. 2022 Oct;30(4):559-574.

Authors

Annemarie M Wensing¹, Vincent Calvez², Francesca Ceccherini-Silberstein³, Charlotte Charpentier⁴, Huldrych F Günthard⁵, Roger Paredes⁶, Robert W Shafer⁷, Douglas D Richman⁸

Affiliations

¹ University Medical Center Utrecht, The Netherlands and Ezintsha, University of the Witwatersrand, Johannesburg, South Africa.
² Pierre et Marie Curie University and Pitié-Salpêtrière Hospital, Paris, France.
³ University of Rome Tor Vergata, Rome, Italy.
⁴ Paris Cité University and Bichat-Claude Bernard Hospital, France.
⁵ University Hospital Zurich and Institute of Medical Virology, University of Zurich, Switzerland.
⁶ HIV Unit and IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
⁷ Stanford University Medical School, California, USA.
⁸ University of California San Diego, San Diego, California, USA.

PMID: 36375130
PMCID: PMC9681141

Abstract

The 2022 edition of the IAS-USA drug resistance mutations list updates the Figure last published in September 2019. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The Figure is designed to assist practitioners to identify key mutations associated with resistance to antiretroviral drugs, and therefore, in making clinical decisions regarding antiretroviral therapy.

MeSH terms

Anti-HIV Agents* / pharmacology
Anti-HIV Agents* / therapeutic use
Drug Resistance, Viral / genetics
HIV Infections* / drug therapy
HIV-1* / genetics
Humans
Mutation

Substances

Anti-HIV Agents

Grants and funding

R24 AI136618/AI/NIAID NIH HHS/United States